Oragenics has published data from studies of its NT-CoV-2-1 proteosome adjuvanted intranasal vaccine candidate against SARS-CoV-2 in mice and hamsters that support further development of the vaccine, the company said. The data were published June 13, 2022 in an article in Nature’s Scientific Reports titled “Intranasal Immunization with a Proteosome-Adjuvanted SARS-CoV2 Spike Protein-Based Vaccine is Immunogenic and Efficacious in Mice & Hamsters.”
In March 2021, the company signed an agreement with Biodextris for use of several mucosal adjuvants in its COVID-19 program. Biodextris has since been acquired by Clean Biologics, and Inspirevax is now developing the proteosome intranasal technology platform. Inspirevax is also partnered with Brigham and Women’s Hospital and I-Mab on the Protollin intranasal vaccine candidate against Alzheimer’s disease.
Oragenics Executive Chairman Frederick W. Telling commented, “We’re proud to have our innovative intranasal vaccine candidate studies published in a reputable, peer-reviewed scientific journal, and believe this heightened recognition underscores the need for vaccines that address the limitations of currently available options. These published data, and our on-going GLP toxicology study will be part of our preclinical data package seeking permission to enter our first-in human clinical trials.”
Read the Oragenics press release.
